{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:38:42Z","timestamp":1790379522974,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"academic health sciences centres of ontario"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24\u00a0h prior to the development of CS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with CS enrolled in the DObutamine compaREd to MIlrinone trial were analyzed. The primary outcome was a composite of all-cause mortality, resuscitated cardiac arrest, need for cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, transient ischemic attack or stroke, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite and hemodynamic response profiles derived from pulmonary artery catheters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 192 participants, 93 patients (48%) had received BB therapy. The primary outcome occurred in 47 patients (51%) in the BB group and in 52 (53%) in the no BB group (RR 0.96; 95% CI 0.73\u20131.27;<jats:italic>P<\/jats:italic>\u2009=\u20090.78) throughout the in-hospital period. There were fewer early deaths in the BB group (RR 0.41; 95% CI 0.18\u20130.95;<jats:italic>P<\/jats:italic>\u2009=\u20090.03). There were no differences in other individual components of the primary outcome or in hemodynamic response between the two groups throughout the remainder of the hospitalization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>BB therapy in the 24\u00a0h preceding the development of CS did not negatively influence clinical outcomes or hemodynamic parameters. On the contrary, BB use was associated with fewer deaths in the early resuscitation period, suggesting a paradoxically protective effect in patients with CS.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>ClinicalTrials.gov Identifier: NCT03207165<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13054-021-03706-2","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:02:50Z","timestamp":1628596970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Pietro","family":"Di Santo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Skanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Daniel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Marbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Razek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Motazedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Parlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Boczar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"D\u2019Egidio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hawken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Bernick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek Y.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"McGuinty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-1363","authenticated-orcid":false,"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CAPITAL DOREMI investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"32","key":"3706_CR1","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/eurheartj\/ehz363","volume":"40","author":"H Thiele","year":"2019","unstructured":"Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671\u201383.","journal-title":"Eur Heart J"},{"issue":"16","key":"3706_CR2","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","volume":"136","author":"S Van Diepen","year":"2017","unstructured":"Van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232\u201368.","journal-title":"Circulation"},{"key":"3706_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1056\/NEJMoa2026845","volume":"385","author":"R Mathew","year":"2021","unstructured":"Mathew R, Di Santo P, Jung RG, et al. Comparison of milrinone and dobutamine in the treatment of cardiogenic shock. N Engl J Med. 2021;385:516\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2026845","journal-title":"N Engl J Med"},{"issue":"6","key":"3706_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA Focused update of the 2013 ACCF\/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776\u2013803.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"3706_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cjca.2017.08.022","volume":"33","author":"JA Ezekowitz","year":"2017","unstructured":"Ezekowitz JA, O\u2019Meara E, McDonald MA, et al. 2017 Comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342\u2013433.","journal-title":"Can J Cardiol"},{"issue":"27","key":"3706_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"21","key":"3706_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64(21):e1\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"3706_CR8","first-page":"CIR.00000000000","volume":"138","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):CIR.00000000000.","journal-title":"Circulation"},{"issue":"12","key":"3706_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"MS Cuffe","year":"2002","unstructured":"Cuffe MS. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA. 2002;287(12):1541.","journal-title":"JAMA"},{"issue":"20","key":"3706_CR10","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","volume":"63","author":"GS Francis","year":"2014","unstructured":"Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol. 2014;63(20):2069\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3706_CR11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","volume":"40","author":"M Metra","year":"2002","unstructured":"Metra M, Nodari S, D\u2019Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. J Am Coll Cardiol. 2002;40(7):1248\u201358.","journal-title":"J Am Coll Cardiol"},{"key":"3706_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ccd.28329","volume":"94","author":"DA Baran","year":"2019","unstructured":"Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheter Cardiovasc Interv. 2019;94:29\u201337.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"3706_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.rec.2018.01.003","volume":"72","author":"SJ Na","year":"2019","unstructured":"Na SJ, Chung CR, Cho YH, et al. Vasoactive inotropic score as a predictor of mortality in adult patients with cardiogenic shock: medical therapy versus ECMO. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2019;72(1):40\u20137.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"issue":"5","key":"3706_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/AC.65.5.2056244","volume":"65","author":"F Gorre","year":"2010","unstructured":"Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action which beta-blocker, when and why? Acta Cardiol. 2010;65(5):565\u201370.","journal-title":"Acta Cardiol"},{"issue":"6","key":"3706_CR15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/01.CIR.74.6.1290","volume":"74","author":"MB Fowler","year":"1986","unstructured":"Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986;74(6):1290\u2013302.","journal-title":"Circulation"},{"issue":"3","key":"3706_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11886-001-0027-8","volume":"3","author":"SF Shakar","year":"2001","unstructured":"Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving \u03b2-blocking agents. Curr Cardiol Rep. 2001;3(3):224\u201331.","journal-title":"Curr Cardiol Rep"},{"issue":"7404","key":"3706_CR17","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bmj.326.7404.1450","volume":"326","author":"J Ducas","year":"2003","unstructured":"Ducas J. Percutaneous coronary intervention: cardiogenic shock. BMJ. 2003;326(7404):1450\u20132.","journal-title":"BMJ"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03706-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-021-03706-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03706-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T05:16:18Z","timestamp":1699334178000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-021-03706-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3706"],"URL":"https:\/\/doi.org\/10.1186\/s13054-021-03706-2","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"29 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Ottawa Health Science Network Research Ethics Board and the study was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from all participants or their substitute decision maker.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}